Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Polycystic Ovary Syndrome 1Motor Activity 1Insulin Resistance 1Body Weight 1

Interventions

Cyclophosphamide 909Carboplatin 786Paclitaxel 741pembrolizumab 741Bevacizumab 715Cisplatin 707Gemcitabine 621Docetaxel 583Rituximab 558Radiotherapy 546Dexamethasone 510Nivolumab 488Doxorubicin 445Fluorouracil 392Capecitabine 382Etoposide 357Pemetrexed 336Oxaliplatin 335Cytarabine 334Lenalidomide 327Prednisone 327Erlotinib Hydrochloride 323fludarabine phosphate 315Trastuzumab 305Leucovorin 299fludarabine 296Vincristine 288Bortezomib 284Filgrastim 284Cetuximab 275

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Caloric Restriction × Clear all
NCT01482286 2022-03-15

PULSE

Pennington Biomedical Research Center

Phase 3 Terminated
32 enrolled 10 charts

Body Weight, Insulin Resistance, Motor Activity, Polycystic Ovary Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡